HC Wainwright Estimates Annexon FY2030 Earnings

Annexon, Inc. (NASDAQ:ANNX) – Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Annexon in a report issued on Thursday, April 2nd. HC Wainwright analyst A. Ghosh forecasts that the company will post earnings per share of $0.43 for the year. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

Annexon (NASDAQ:ANNX) last issued its earnings results on Monday, March 30th. The company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04.

ANNX has been the subject of a number of other reports. Chardan Capital reiterated a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Friday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.00.

Annexon Stock Up 2.6%

Shares of Annexon stock opened at $5.50 on Friday. Annexon has a twelve month low of $1.28 and a twelve month high of $7.18. The company’s 50 day moving average is $5.55 and its 200 day moving average is $4.57. The company has a market cap of $657.97 million, a price-to-earnings ratio of -4.04 and a beta of 1.14.

Insider Buying and Selling at Annexon

In other Annexon news, EVP Dean Richard Artis sold 5,290 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total value of $26,979.00. Following the transaction, the executive vice president directly owned 123,487 shares in the company, valued at approximately $629,783.70. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William H. Carson acquired 8,000 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $5.67 per share, with a total value of $45,360.00. Following the transaction, the director owned 62,405 shares in the company, valued at approximately $353,836.35. This trade represents a 14.70% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders sold 32,513 shares of company stock valued at $165,973 in the last quarter. Insiders own 11.87% of the company’s stock.

Institutional Trading of Annexon

Hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC raised its stake in shares of Annexon by 122.6% in the first quarter. AQR Capital Management LLC now owns 73,790 shares of the company’s stock worth $142,000 after buying an additional 40,637 shares during the period. Jane Street Group LLC grew its stake in shares of Annexon by 8.2% during the 1st quarter. Jane Street Group LLC now owns 99,924 shares of the company’s stock valued at $193,000 after acquiring an additional 7,553 shares during the period. Acadian Asset Management LLC increased its holdings in Annexon by 31.1% in the 1st quarter. Acadian Asset Management LLC now owns 203,990 shares of the company’s stock worth $393,000 after acquiring an additional 48,345 shares in the last quarter. Geode Capital Management LLC raised its stake in Annexon by 1.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,284,773 shares of the company’s stock worth $5,484,000 after acquiring an additional 39,763 shares during the period. Finally, American Century Companies Inc. lifted its holdings in Annexon by 6.6% during the second quarter. American Century Companies Inc. now owns 211,195 shares of the company’s stock valued at $507,000 after purchasing an additional 13,001 shares in the last quarter.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.